|
Press Releases |
|
![](/images/company/nanobiotix.jpg) |
|
Saturday, August 31, 2013 |
|
NANOBIOTIX: Half Year Results for the Period Ended 30 June 2013 |
NANOBIOTIX (the "Company") (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, has published today its half year results for the six month period ended 30 June 2013 (HY1). more info >> |
|
Thursday, July 4, 2013 |
|
Nanobiotix Announces EUR 2.8 Million Grant from bpifrance to Accelerate Development of NBTXR3 in a Third New Indication |
NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today it has secured c.EUR 9 million in funding from bpifrance (formerly OSEO) of which EUR 2.8 million is directly attributable to the Company. more info >> |
|
Wednesday, June 26, 2013 |
|
Nanobiotix Announces the Selection of its Second NanoXray Product, NBTX-IV and a Collaboration with the National Cancer Institute for Development |
NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces the selection of a new product for development, NBTX-IV. more info >> |
|
Thursday, June 13, 2013 |
|
Nanobiotix Receives Approval from ANSM to Start New Clinical Trial with Lead Product NBTXR3 |
NANOBIOTIX (Euronext: NANO) announces today that its lead compound NBTXR3 has received authorization from the French Medicine Agency, ANSM, to start a clinical trial in patients with locally advanced cancers of the oral cavity or oropharynx (head and neck cancer), at the Institut Curie, Paris, France, a French leading cancer treatment center. more info >> |
|
Monday, June 3, 2013 |
|
Nanobiotix's NBTXR3 Achieves Clinical Milestone Reaching Proof-Of-Concept in Phase I Trial of Soft Tissue Sarcoma |
NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces positive Phase I interim results of its lead nanoparticle-based product, NBTXR3, in patients with Soft Tissue Sarcoma (STS). more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Best BLUETTI Prime Day Deals on Portable Power Stations and Solar Generators
Jul 16, 2024 22:00 HKT/SGT
|
|
|
Lexaria Preparing For Strategic Growth
Jul 16, 2024 21:20 HKT/SGT
|
|
|
'Alamein Festival' Launches Exciting Second Edition for 2024
Jul 16, 2024 21:00 HKT/SGT
|
|
|
China Medical System (867.HK) Reincluded in S&P Global Sustainability Yearbook (China Edition) and Maintained MSCI ESG "AA" Rating
Jul 16, 2024 21:00: JST
|
|
|
China Medical System (867.HK) Reincluded in S&P Global Sustainability Yearbook (China Edition) and Maintained MSCI ESG "AA" Rating
Jul 16, 2024 20:00 HKT/SGT
|
|
|
How Artificial Intelligence Can Help Give Your Business a Boost
Jul 16, 2024 19:30 HKT/SGT
|
|
|
U.S. Polo Assn. Proudly Partners with the 2024 Outsourcing Inc. Royal Charity Polo Cup
Jul 16, 2024 19:00 HKT/SGT
|
|
|
Neste and Mitsubishi Corporation agree on strategic partnership to develop supply chains for renewable chemicals and plastics
Jul 16, 2024 18:36 JST
|
|
|
NEC technology reliably measures sea levels from a greater distance
Jul 16, 2024 17:45 JST
|
|
|
全球发展数字经济直播访谈会正式举办 外方来华参会高级别代表走进东方甄选直播间
Jul 16, 2024 15:08 HKT/SGT
|
|
|
巨星傳奇(6683.HK)解禁後首個交易日 收盤報10.4港元 升幅達2.97%
Jul 16, 2024 15:04 HKT/SGT
|
|
|
巨星传奇(6683.HK)解禁后首个交易日: 收盘报10.4港元 升幅达2.97%
Jul 16, 2024 14:58 HKT/SGT
|
|
|
全球發展數字經濟直播訪談會正式舉辦 外方來華參會高級別代表走進東方甄選直播間
Jul 16, 2024 14:25 HKT/SGT
|
|
|
Fujitsu and Cohere launch strategic partnership and joint development to provide generative AI for enterprises
Jul 16, 2024 15:13 JST
|
|
|
Komisi Penerbangan Malaysia Memilih TransNusa Sebagai Salah Satu Dari Dua Maskapai Asing Untuk Meluncurkan Penerbangan Dari Bandara Subang
Jul 16, 2024 14:00 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|